$CI

Jones Nicole S sold $5.4M of CI

Jones Nicole S (See Remarks) sold 19,436 shares of Cigna Group (CI) at $276.27 ($5.37M total) on 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jones Nicole S
Published Aug 6, 2026, 8:31 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CI
Neutral
high confidence
Mentioned
$CI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CINeutralLow
01

Why it matters

The newest concrete fact is the sale size ($5.37M) and execution details (19,436 shares at $276.27) with a pre-arranged plan, which generally reduces informational content about near-term business outlook.

02

Market read

Traders may note the filing for sentiment monitoring, but it is unlikely to drive a fundamental repricing without accompanying company-specific news.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no reason for sale, and no follow-on purchases, limiting interpretability.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-06 for a sale executed 2026-08-04.

Background

The article is an SEC Form 4 insider transaction disclosure for Cigna Group, reporting an officer’s open-market sale executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CINeutralHigh confidence
Context

Cigna Group Form 4 shows officer Jones Nicole S sold 19,436 shares at $276.27 on 2026-08-04 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move based solely on this filing.

Evidence & confidence

The filing is a routine insider transaction with an explicit 10b5-1 pre-arranged plan; it does not disclose new company performance, guidance, or regulatory developments.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or earnings changes.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, large dollar-value insider selling can still coincide with private views on risk or liquidity needs, so some traders may briefly fade the stock.

Key entities

  • Cigna Group

    CI, the company whose Form 4 insider sale is disclosed.

  • Jones Nicole S

    Officer who sold 19,436 shares under a 10b5-1 plan.

Related articles

$CIMed

Cigna: Specialty Care Profit Jumps 22% As Pharmacy Benefit Earnings Fall 27%

Cigna reported Q2 2026 results showing profit divergence within Evernorth. Specialty and Care Services adjusted pre-tax operating income rose 22% to $1.05B on $26.97B revenue, while Pharmacy Benefit Services operating income fell 27% to $609M on $34.5B revenue. Total Evernorth adjusted revenue rose 6% to $61.47B, but operating income fell 2%. Cigna raised FY2026 adjusted EPS outlook to at least $30.45.

$CIMed

Why is Cigna stock sliding today?

Cigna Corp shares fell 2.7% after its pre-market Q2 report. Adjusted EPS was $7.78 vs about $7.59 expected, and revenue rose 7% to $71.7B vs about $70.18B. Cigna raised full-year 2026 adjusted EPS outlook to at least $30.45. Higher medical care ratio, nonrecurring specialty generic benefit, and $59.4M insider selling weighed on sentiment.